134 related articles for article (PubMed ID: 35211595)
1. Tumor-related cytokine release syndrome in a treatment-naïve patient with lung adenocarcinoma: A case report.
Deng PB; Jiang J; Hu CP; Cao LM; Li M
World J Clin Cases; 2022 Feb; 10(5):1580-1585. PubMed ID: 35211595
[TBL] [Abstract][Full Text] [Related]
2. A case of cytokine release syndrome accompanied with COVID-19 infection during treatment with immune checkpoint inhibitors for non-small cell lung cancer.
Murata D; Azuma K; Tokisawa S; Tokito T; Hoshino T
Thorac Cancer; 2022 Oct; 13(20):2911-2914. PubMed ID: 36073307
[TBL] [Abstract][Full Text] [Related]
3. Cytokine release syndrome induced by immune checkpoint inhibitor treatment for uterine cervical cancer recurrence: A case report.
Sekimata M; Kinjo Y; Tohyama A; Murakami M; Hashiwaki S; Saito Y; Higami S; Hagimoto M; Taketomi R; Hoshino K; Harada H; Ueda T; Kurita T; Matsuura Y; Yoshino K
Oncol Lett; 2024 Jul; 28(1):331. PubMed ID: 38807673
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab-Induced Cytokine Release Syndrome: A Case Report and Literature Review.
Ntwali F; Gilliaux Q; Honoré PM
Am J Case Rep; 2024 Apr; 25():e941835. PubMed ID: 38625840
[TBL] [Abstract][Full Text] [Related]
5. Cytokine release syndrome after radiation therapy: case report and review of the literature.
Barker CA; Kim SK; Budhu S; Matsoukas K; Daniyan AF; D'Angelo SP
J Immunother Cancer; 2018 Jan; 6(1):1. PubMed ID: 29298730
[TBL] [Abstract][Full Text] [Related]
6. Cytokine release syndrome in a patient with non-small cell lung cancer on ipilimumab and nivolumab maintenance therapy after vaccination with the mRNA-1273 vaccine: a case report.
Sumi T; Koshino Y; Michimata H; Nagayama D; Watanabe H; Yamada Y; Chiba H
Transl Lung Cancer Res; 2022 Sep; 11(9):1973-1976. PubMed ID: 36248324
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab-induced cytokine release syndrome in a patient with metastatic lung adenocarcinoma: a case report.
Sackstein P; Zaemes J; Kim C
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34330765
[TBL] [Abstract][Full Text] [Related]
8. Fatal cytokine-release syndrome in a patient receiving toripalimab: a case report.
Zhou Y; Zheng GH; Li N; Liu JJ; Wang XH; Li YF
Immunotherapy; 2023 Jun; 15(9):641-645. PubMed ID: 37139989
[TBL] [Abstract][Full Text] [Related]
9. First Case of Cytokine Release Syndrome after Nivolumab for Gastric Cancer.
Oda H; Ishihara M; Miyahara Y; Nakamura J; Kozuka Y; Iwasa M; Tsunoda A; Yamashita Y; Saito K; Mizuno T; Shiku H; Katayama N
Case Rep Oncol; 2019; 12(1):147-156. PubMed ID: 31043953
[TBL] [Abstract][Full Text] [Related]
10. Tocilizumab for severe cytokine-release syndrome after haploidentical donor transplantation in a patient with refractory Epstein-Barr virus-positive diffuse large B-cell lymphoma.
Ureshino H; Ando T; Kizuka H; Kusaba K; Sano H; Nishioka A; Itamura H; Shindo T; Kubota Y; Kojima K; Kimura S
Hematol Oncol; 2018 Feb; 36(1):324-327. PubMed ID: 28971493
[TBL] [Abstract][Full Text] [Related]
11. Successful Treatment of Cytokine Release Syndrome with IL-6 Blockade in a Patient Transitioning from Immune-Checkpoint to MEK/BRAF Inhibition: A Case Report and Review of Literature.
Amlani A; Barber C; Fifi-Mah A; Monzon J
Oncologist; 2020 Jul; 25(7):e1120-e1123. PubMed ID: 32337758
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab-related severe thrombocytopenia in a patient with relapsed lung adenocarcinoma: a case report and review of the literature.
Hasegawa T; Ozaki Y; Inoue T; Watanabe Y; Fukuhara M; Yamaura T; Muto S; Okabe N; Higuchi M; Shio Y; Suzuki H
J Med Case Rep; 2019 Oct; 13(1):316. PubMed ID: 31647029
[TBL] [Abstract][Full Text] [Related]
13. "Small" Intestinal Immunopathology Plays a "Big" Role in Lethal Cytokine Release Syndrome, and Its Modulation by Interferon-γ, IL-17A, and a Janus Kinase Inhibitor.
Kale SD; Mehrkens BN; Stegman MM; Kastelberg B; Carnes H; McNeill RJ; Rizzo A; Karyala SV; Coutermarsh-Ott S; Fretz JA; Sun Y; Koff JL; Rajagopalan G
Front Immunol; 2020; 11():1311. PubMed ID: 32676080
[TBL] [Abstract][Full Text] [Related]
14. Cytokine release syndrome induced by pembrolizumab: A case report.
Zhang X; Fu Z; Yan C
Medicine (Baltimore); 2022 Dec; 101(49):e31998. PubMed ID: 36626467
[TBL] [Abstract][Full Text] [Related]
15. Cytokine Release Syndrome More than Two Years after Pembrolizumab Introduction: A Case Report.
Nakashima K; Kitani K; Kono K; Yoshihara K; Kawakado K; Kobayashi M; Okuno T; Amano Y; Tsubata Y; Isobe T
Intern Med; 2023 Dec; ():. PubMed ID: 38104995
[TBL] [Abstract][Full Text] [Related]
16. Anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: A case report.
Osaki M; Tachikawa R; Ohira J; Hara S; Tomii K
Invest New Drugs; 2021 Feb; 39(1):251-255. PubMed ID: 32651759
[TBL] [Abstract][Full Text] [Related]
17. Severe cytokine release syndrome induced by immune checkpoint inhibitors in cancer patients - A case report and review of the literature.
Zhang Y; Wen X; OuYang Y; Hu Y; Fang X; Zhang J; Yuan Y
Heliyon; 2024 Jan; 10(2):e24380. PubMed ID: 38293388
[TBL] [Abstract][Full Text] [Related]
18. Acute cytokine release syndrome after a first dose of pembrolizumab as second-line treatment for metastatic, programmed death-ligand 1-positive, non-small-cell lung cancer.
Normand CV; Zender HO; Staehli DM; Chouiter-Djebaili AF; John G
J Oncol Pharm Pract; 2021 Sep; 27(6):1528-1533. PubMed ID: 33353504
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
[TBL] [Abstract][Full Text] [Related]
20. Severe cytokine release syndrome in a patient receiving PD-1-directed therapy.
Rotz SJ; Leino D; Szabo S; Mangino JL; Turpin BK; Pressey JG
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28544595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
